Articles
Early Access
The role of a multidisciplinary approach in non-melanoma skin cancer management
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Published: 23 February 2026
355
Views
156
Downloads
Authors
A multidisciplinary team (MDT) is fundamental for properly managing non-melanoma skin cancer (NMSC). Surgery is the first treatment choice for early-stage disease; however, in cases with a high risk of recurrence or when demolitive approaches would not achieve safe margins, radiotherapy (RT) or an MDT approach is required. We retrospectively revised the population evaluated at our weekly MDT meeting, and all patients were discussed. A case series of 130 patients visited from July 2021 to March 2024 was collected. In-person visits were performed. The male/female ratio was 69.5/31.5%. Elderly patients prevailed: the mean age was 79 years (range 29-102 years). Patients affected by Gorlin syndrome were 7, and solid transplant recipients were 4. Among patients, 66 were diagnosed with cutaneous squamous cell carcinoma (SCC) (58%), 52 had basal cell carcinoma (BCC) (40%), and 12 had both SCC and BCC (9.2%). Among patients with SCC, 24 received primary surgery (36.4%), 11 received RT (16.6%), and 25 were candidates for treatment with cemiplimab (37.9%). Six patients (9.1%) were indicated to undertake a dermatological follow-up associated with best supportive care for comorbidities and performance status.
Downloads
Download data is not yet available.
Citations
1. Hughes BGM, Guminski A, Bowyer S, et al. A phase 2 open-label study of cemiplimab in patients with advanced cutaneous squamous cell carcinoma (EMPOWER-CSCC-1): Final long-term analysis of groups 1, 2, and 3, and primary analysis of fixed-dose treatment group 6. J Am Acad Dermatol 2025;92:68-77.
2. Chang JH, Vines E, Bertsch H, et al. The impact of a multidisciplinary breast cancer center on recommendations for patient management: the University of Pennsylvania experience. Cancer 2001;91:1231-7.
3. Dietz DW; Consortium for Optimizing Surgical Treatment of Rectal Cancer (OSTRiCh). Multidisciplinary management of rectal cancer: the OSTRICH. J Gastrointest Surg 2013;17:1863-8.
4. Engelhardt M, Ihorst G, Schumacher M, et al. Multidisciplinary tumor boards and their analyses: the yin and yang of outcome measures. BMC Cancer 2021;21:173.
5. Sassun R, Sileo A, Ng JC, et al. Multidisciplinary Management of Anorectal Melanoma: a Retrospective Analysis of Surgical and Systemic Therapies from the National Cancer Database. J Gastrointest Cancer 2025;56:108.
6. Pangarsa EA, Rizky D, Tandarto K, et al. The effect of multidisciplinary team on survival rates of women with breast cancer: a systematic review and meta-analysis. Ann Med Surg (Lond) 2023;85:2940-8.
7. Rudolph V, Leven AS, Eisenburger R, et al. Interdisciplinary management of skin cancer. Laryngorhinootologie 2024;103:S100-24. English, German.
8. Chin YR, Dickson J. A diagrammatic summary of updated NICE melanoma guidance: A simple way to mitigate human factors in MDTs and clinics. J Plast Reconstr Aesthet Surg 2023;81:85-7.
9. Liu JC, Kaplon A, Blackman E, et al. The impact of the multidisciplinary tumor board on head and neck cancer outcomes. Laryngoscope 2020;130:946-50.
10. Mittal A, Mittal BB. Comparative Analysis of US Guidelines for the Management of Cutaneous Squamous Cell and Basal Cell Carcinoma. J Skin Cancer 2024;2024:3859066.
11. Migden MR, Khushalani NI, Chang ALS, et al. Cemiplimab in locally advanced cutaneous squamous cell carcinoma: results from an open-label, phase 2, single-arm trial. Lancet Oncol 2020;21:294-305.
12. Mager L, Gardeen S, Carr DR, Shahwan KT. Cemiplimab for the Treatment of Advanced Cutaneous Squamous Cell Carcinoma: Appropriate Patient Selection and Perspectives. Clin Cosmet Investig Dermatol 2023;16:2135-42.
13. Vasudevan SS, Patel T, DiGiovanni J, et al. Current Efficacy, Safety and Survival Outcomes of Cemiplimab in Advanced Cutaneous Squamous Cell Carcinoma: A Systematic Review and Meta-analysis. Invest Dermatol 2025;145:2623-6.e5.
14. Baggi A, Quaglino P, Rubatto M, et al. Real world data of cemiplimab in locally advanced and metastatic cutaneous squamous cell carcinoma. Eur J Cancer 2021;157:250-8. Erratum in: Eur J Cancer 2022;166:309-10.
15. Sekulic A, Migden MR, Basset-Seguin N, et al.; ERIVANCE BCC Investigators. Long-term safety and efficacy of vismodegib in patients with advanced basal cell carcinoma: final update of the pivotal ERIVANCE BCC study. BMC Cancer 2017;17:332.
16. Dummer R, Guminski A, Gutzmer R, et al. The 12-month analysis from Basal Cell Carcinoma Outcomes with LDE225 Treatment (BOLT): A phase II, randomized, double-blind study of sonidegib in patients with advanced basal cell carcinoma. J Am Acad Dermatol 2016;75:113-25.e5.
17. Bossi P, Ascierto PA, Basset-Seguin N, et al. Long-term strategies for management of advanced basal cell carcinoma with hedgehog inhibitors. Crit Rev Oncol Hematol 2023;189:104066.
18. Denaro N, Passoni E, Indini A, et al. Cemiplimab in Ultra-Octogenarian Patients with Cutaneous Squamous Cell Carcinoma: The Real-Life Experience of a Tertiary Referral Center. Vaccines (Basel) 2023;11:1500.
19. Li J, Stanger BZ. How Tumor Cell Dedifferentiation Drives Immune Evasion and Resistance to Immunotherapy. Cancer Res 2020;80:4037-41.
20. Zelin E, Maronese CA, Dri A, et al. Identifying Candidates for Immunotherapy among Patients with Non-Melanoma Skin Cancer: A Review of the Potential Predictors of Response. J Clin Med 2022;11:3364.
21. Strippoli S, Fanizzi A, Quaresmini D, et al. Cemiplimab in an Elderly Frail Population of Patients With Locally Advanced or Metastatic Cutaneous Squamous Cell Carcinoma: A Single-Center Real-Life Experience From Italy. Front Oncol 2021;11:686308.
22. Koch Hein EC, Vilbert M, Hirsch I, et al. Immune Checkpoint Inhibitors in Advanced Cutaneous Squamous Cell Carcinoma: Real-World Experience from a Canadian Comprehensive Cancer Centre. Cancers (Basel) 2023;15:4312.
23. Rohaan MW, Duizer ML, Devriese LA, et al. Real-world data on tolerability and clinical response of cemiplimab in patients with advanced cutaneous squamous cell carcinoma: A retrospective, multicentre cohort study from the Netherlands. EJC Skin Cancer 2023;1:100007.
24. McLean LS, Lim AM, Bressel M, et al. Real-World Experience of Immune-Checkpoint Inhibitors in Older Patients with Advanced Cutaneous Squamous Cell Carcinoma. Drugs Aging 2024;41:271-81.
25. Haist M, Stege H, Lang BM, et al. Response to First-Line Treatment with Immune-Checkpoint Inhibitors in Patients with Advanced Cutaneous Squamous Cell Carcinoma: A Multicenter, Retrospective Analysis from the German ADOReg Registry. Cancers (Basel) 2022;14:5543.
26. Rischin D, Migden MR, Lim AM, et al. Phase 2 study of cemiplimab in patients with metastatic cutaneous squamous cell carcinoma: primary analysis of fixed-dosing, long- term outcome of weight-based dosing. J Immunother Cancer 2020;8:e000775.
27. Gross ND, Miller DM, Khushalani NI, et al. Neoadjuvant cemiplimab and surgery for stage II-IV cutaneous squamous-cell carcinoma: follow-up and survival outcomes of a single-arm, multicentre, phase 2 study. Lancet Oncol 2023;24:1196-205.
28. Hober C, Fredeau L, Pham-Ledard A, et al. Cemiplimab for Locally Advanced and Metastatic Cutaneous Squamous-Cell Carcinomas: Real-Life Experience from the French CAREPI Study Group. Cancers (Basel) 2021;13:3547.
29. Kuzmanovszki D, Kiss N, Tóth B, et al. Real-World Experience with Cemiplimab Treatment for Advanced Cutaneous Squamous Cell Carcinoma - A Retrospective Single-Center Study. J Clin Med 2023;12:5966.
30. Averbuch I, Salman S, Shtamper N, et al. First-line programmed death-1 inhibitor treatment for locoregionally advanced or metastatic cutaneous squamous cell carcinoma - A real-world experience from Israel. Front Oncol 2023;13:1117804.
31. Hanna GJ, Dharanesswaran H, Giobbie-Hurder A, et al. Cemiplimab for Kidney Transplant Recipients With Advanced Cutaneous Squamous Cell Carcinoma. J Clin Oncol 2024;42:1021-30.
32. Van Meerhaeghe T, Baurain JF, Bechter O, et al. Cemiplimab for advanced cutaneous squamous cell carcinoma in kidney transplant recipients. Front Nephrol 2022;2:1041819.
How to Cite
1.
Lussana F, Denaro N, Passoni E, Murgia G, Benzecry V, Bortoluzzi P, et al. The role of a multidisciplinary approach in non-melanoma skin cancer management. Dermatol Reports [Internet]. 2026 Feb. 23 [cited 2026 May 26];. Available from: https://journals.pagepress.net/dr/article/view/10161
Copyright (c) 2026 the Author(s)
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
